ApoE4 Glia Bungle Lipid Processing, Mess with the Matrisome
The phenotype of ApoE4 astrocytes and microglia resembles that of these cells in Alzheimer’s brain. Could defects in lipid metabolism and the extracellular matrix bring on the disease?
ALL NEWS
5423 RESULTS
Sort By:
- Most Recent
- Most Commented
Paper Alert: MS4A Variants May Sway Alzheimer’s Risk Via TREM2
Different polymorphisms in MS4A genes up- or down-regulate levels of TREM2, modulating levels of the shed ectodomain in the cerebrospinal fluid and AD risk.
Geneticists Seek Out Rare Contributors to Alzheimer’s
New genes linked to early- and late-onset AD offer up mechanistic insight, potential targets for treatment.
Triple Threat: Tau, Atrophy, and Arteriolosclerosis Push CTE Toward Dementia
Among former National Football League players who died with CTE, tau tangles, crumbling white matter, and arteriolosclerosis independently contributed to dementia.
AD Genetic Risk Tied to Changes in Microglial Gene Expression
Functional variants of AD GWAS hits found in enhancers of myeloid genes.
Aβ Dimers Block Glutamate Uptake, Fire Up Synapses
New evidence suggests the dimers impede clearance of glutamate from synapses, contributing to the hyperexcitability seen early in Alzheimer’s disease.
Rare Luck: Two Copies of ApoE2 Shield Against Alzheimer’s
ApoE2 homozygotes have a dramatically lower risk of AD than even the previously known low-risk E2/3 heterozygotes. More study of this protective allele could reveal roots of resilience.
Colombian Cohort Delivers Data on Blood NfL
In 2,144 Colombian ADAD family members, plasma NfL in gene carriers rises as early as two decades before their symptoms start.
Crenezumab Update: Baseline Data from Colombian Prevention Trial
At AAIC, researchers presented baseline data from an ongoing, five-year study asking whether the anti-Aβ antibody crenezumab can forestall cognitive decline in autosomal-dominant Alzheimer’s disease.
Colleagues Mourn Loss of Rahul Desikan, Age 41, to ALS
Desikan pioneered advances in neuroimaging and neurogenetics, and was known for his passion and collaborative spirit.
As DIAN Wraps Up Anti-Aβ Drug Arms, it Sprouts Tau, Primary Prevention Arms
The DIAN Trials Unit is nearing the end of its first two secondary prevention trials. It has begun a cognitive run-in period for its next trial, of a tau-based drug, and for a primary prevention study in people as young as 18.
ASOs: Wave of the Future in Alzheimer’s Therapeutics?
As the Alzheimer’s field suffers smackdowns in trials of small molecules and antibodies, antisense oligonucleotides are quietly coming along—and looking safe so far.
Genetics Propels DIAN Toward Therapies
Nearly 30 years after the first Alzheimer’s gene discoveries, genetics once again drives recruitment, scientific progress, and therapy development in the Dominantly Inherited Alzheimer’s Network.
DIAD: Families from Argentina, Canada, Minnesota Rally a Global Community
A brother’s survival guilt, a journalist tracing her mutation to Lebanon, a student freezing her eggs ahead of a primary prevention trial—DIAN family members are stirring their growing community to act against Alzheimer’s disease.
High and Low Hemoglobin Levels Tied to Alzheimer’s
Too much or too little serum hemoglobin increases risk for Alzheimer’s and other dementias by 20 percent or more.
Current Filters
No filters selected